A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis

American Journal of Gastroenterology

Volumn 98, Issue 2, 2003, Pages 369-376

  Van Assche, Gert ^a,b   Dalle, Ignace ^a   Noman, Maja ^a   Aerden, Isolde ^a   Swijsen, Caroline ^a   Asnong, Katrien ^a   Maes, Bart ^a   Ceuppens, Jan ^a   Geboes, Karel ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR; MERCAPTOPURINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; FEMALE; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NAUSEA; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SCORING SYSTEM; SIGMOIDOSCOPY; ULCERATIVE COLITIS;

EID: 0037285975     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)05907-5     Document Type: Article

References (19)

1. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998;115:182-205.
2. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological and histological parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20.
3. Rutgeerts P. Medical therapy of inflammatory bowel disease. Digestion 1998;59:453-69.
4. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Eng J Med 1994;330:1841-5.
5. Sandborn WJ. A critical review of cyclosporin therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995;1:48-63.
6. D'Haens G, Lemmens L, Geboes K, et al. Inravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120:1323-9.
7. Daclizumab, Investigator's Brochure. March, 2001.
8. Maes B, Vanrenterghem Y. Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation. Nephrol Dial Transplant 1999;14:2824-6.
9. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161-5.
10. Rachmilewitz D. Coated mesalazine versus sulphasalazine in the treatment of active ulcerative colitis. Br Med J 1989;298: 82-6.
11. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
12. Geboes K, Riddell R, Öst A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404-9.
13. Savo AM, Book BK, Henson S, et al. Daclizumab rapidly saturates interleukin-2-a (CD25) on lymph node lymphocytes in children. Transplant Proc 1999;31:1182-3.
14. Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: Recent developments in molecular action and clinical application. Transplant Proc 1998;30:1573-9.
15. Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
16. Willerford DM, Chen J, Ferry JA, et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid component. Immunity 1995;3:521-30.
17. Poussier P, Ning T, Chen J, et al. Intestinal inflammation in IL-2R/IL-2 mutant mice is associated with impaired intestinal T lymphopoiesis. Gastroenterology 2000;118:880-91.
18. Stallmach A, Wittig B, Giese T, et al. Protection of trinitrobenzene sulfonic acid-induced colitis by interleukin 2-IgG2b fusion protein in mice. Gastroenterology 1999;117:866-76.
19. Kronenberg M, Cheroutre H. Do mucosal T cells prevent intestinal inflammation? Gastroenterology 2000;118:974-7.